Woods NF, LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Brunner RL, et al. Frailty: emergence and consequences in women aged 65 and older in the Women’s health initiative observational study. J Am Geriatr Soc. 2005;53:1321–30.
Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Cardiovascular health study collaborative research group. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146–56.
Rockwood K, Howlett SE, MacKnight C, Beattie BL, Bergman H. He bert R, et al. prevalence, attributes, and outcomes of fitness and frailty in community-dwelling older adults: report from the Canadian study of health and aging. J Geront A Biol Sci Med Sci. 2004;59(12):1310–7.
Yanagita I, Fujihara Y, Eda T, Tajima M, Yonemura K, Kawajiri T, et al. Low glycated hemoglobin level is associated with severity of frailty in Japanese elderly diabetes patients. J Diabetes Investig. 2018;9(2):419–25.
Yanase T, Yanagita I, Muta K, Nawata H. Frailty in elderly diabetes patients. Endocr J. 2018;65:1–11.
Abdelhafiz AH, Loo BE, Hensey N, Bailey C, Sinclair A. The U -shaped relationship of traditional cardiovascular risk factors and adverse outcomes in later life. Aging Dis. 2012;3(6):454–64.
Abdelhafiz AH, Sinclair AJ. Low HbAlc and increased mortality risk-is frailty a confounding factor? Aging Dis. 2015;6(4):262–70.
Liguori I, Russo G, Aran L, Bulli G, Curcio F, Della-Morte D, et al. Sarcopenia: assessment of disease burden and strategies to improve outcomes. Clin Interv Aging. 2018;13:913–27.
Yanagita I, Fujihara Y, Kitajima Y, Tajima M, Honda M, Kawajiri T, et al. A high serum cortisol/DHEA-S ratio is a risk factor for sarcopenia in elderly diabetic patients. J Endocrine Soc. 2019;3(4):801–13.
Orentreich N, Brind JL, Rizer RL, Vogelman JH. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentration throughout adulthood. J Clin Endocrinol Metab. 1984;59:551–5.
Nawata H, Yanase T, Goto K, Okabe T, Ashida K. Mechanism of action of anti-aging DHEA-S and the replacement of DHEA-S. Mech Aging Dis. 2002;123:1101–6.
Leng SX, Cappola AR, Andersen RE, Blackman MR, Koenig K, Blair M, et al. Serum levels of insulin-like growth factor-l (IGF-1) and dehydroepiandrosterone sulfate (DHEA-S), and their relationships with serum interleukin-6, in the geriatric syndrome of frailty. Aging Clin Exp Res. 2004;16(2):153–7.
Voznesensky M, Walsh A, Dauser D, Brindisi J, Kenny AM. The relationship between dehydroepiandrosterone and frailty in older men and women. Age Ageing. 2009;38(4):401–6.
Baylis D, Bartlett DB, Syddall HE, Ntani G, Gale CR, Cooper C, et al. Immune-endocrine biomarkers as predictors of frailty and mortality: a 10-year longitudinal study in community-dwelling older people. Age. 2013;35:963–71.
Swiecicka A, Lunt M, Ahern T, O’Neill TW, Bartfai G, Casanueva FF, et al. Nonandrogenic anabolic hormones predict risk of frailty: European male ageing study prospective data. J Clin Endocrinol Metab. 2017;102(8):2799–806.
Forti P, Maltoni B, Olivelli V, Pirazzoli GL, Ravaglia G, Zoli M. Serum dehydroepiandrosterone sulfate and adverse health outcomes in older men and women. Rejuvenation Res. 2012;15(4):349–58.
Seino Y, Nanjo K, Tajima N, Kadowaki T, Kashiwagi A, Araki E, et al. Committee of the Japan Diabetes Society on the diagnostic criteria of diabetes mellitus: report of the committee on the classification and diagnostic criteria of diabetes mellitus. J Diabetes Investig. 2010;1(5):212–28.
Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. European working group on sarcopenia in older people. Sarcopenia: European consensus on definition and diagnosis: report of the European working group on sarcopenia in older people. Age Ageing. 2010;39(4):412–23.
Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian working Group for Sarcopenia. J Am Med Dir Assoc. 2014;15(2):95–101.
Akirov A, Masri-Iraqi H, Atamna A, Shimon I. Low albumin levels are associated with mortality risk i hospitalized patients. Am J Med. 2017;130(12):1465. https://doi.org/10.1016/j.amjmed.
Le Couteur DG, Blyth FM, Creasey HM, Handelsman DJ, Naganathan V, Sambrook PN, et al. The association of alanine transaminase with aging, frailty, and mortality. J Gerontol A Biol Sci Med Sci. 2010;65(7):712–7.
Vespasiani-Gentilucci U, De Vincentis A, Ferrucci L, Bandinelli S, Antonelli Incalzi R, Picardi A. Low alanine aminotransferase levels in the elderly population: frailty, disability, sarcopenia and reduced survival. J Gerontol A Biol Med Sci. 2018;73(7):925–30.
Elinav E, Ackerman Z, Maaravi Y, Ben-Dov IZ, Ein-Mor E, Stessman J. Low alanine aminotransferase activity in older people is associate with greater long-term mortality. J Am Geriatr Soc. 2006;54(11):1719–24.
Vanderlinde RE. Review of pyridoxal phosphate and the transaminases in liver disease. Ann Clin Lab Sci. 1986;16(2):79–93.
Kjeldby IK, Fosnes GS, Ligaarden SC, Farup PG. Vitamin B6 deficiency and diseases in elderly people--a study in nursing homes. BMC Geriatr. 2013;13:13. https://doi.org/10.1186/1471-2318-13-13.
Fukui M, Ose H, Nakayama I, Hosoda H, Asano M, Kadono M, et al. Association between urinary albumin excretion and serum dehydroepiandrosterone sulfate concentrations in women with type 2 diabetes. Diabetes Care. 2007;30(7):1886–8.
Charlton M, Angulo P, Chalasani N, Merriman R, Viker K, Charatcharoenwitthaya P, et al. Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology. 2008;47:484–92.
Sumida Y, Naitoa Y, Hashimoto E, Aoi W, Takahashi Y, Yonei Y, et al. Science of nonalcoholic fatty liver disease in anti-aging medicine 2011. Anti-aging Medicine. 2012;9:24–33.
Hakkak R, Bell A, Korourian S. Dehydroepiandrosterone (DHEA) feeding protects liver steatosis in obese breast cancer rat model. Sci Pharm. 2017;85:13–22.
Teng Y, Radde BN, Litchfield LM, Ivanova MM, Prough RA, Clark BJ, et al. Dehydroepiandrosterone activation of G-protein-coupled estrogen receptor rapidly stimulate microRNA-21 transcription in human hepatocellular carcinoma cells. J Biol Chem. 2015;290:15799–811.
Ong KK. Potau N, Petry CJ, Jones R, ness AR, honour JW, et al. opposing influence of prenatal and postnatal weight gain on adrenarche in normal boys and girls. J Clin Endocrinol Metab. 2004;89:2647–51.
Corvalan C, Uauy R, Mericq V. Obesity is positively associated with dehydroepiandrosterone sulfate concentrations at 7 y in Chilean children of normal birth weight. Am J Clin Nutr. 2013;97:318–25.
Jarecki P, Herman WA, Pawliczak E, Lacka K. Can low SHBG serum concentration be a good early marker of male hypogonadism in metabolic syndrome? Diabetes Metab Syndr Obes. 2019;2:2181. https://doi.org/10.2147/DMSO.S218545.
Taniguchi S, Yanase T, Haji M, Ishibashi K, Takayanagi R, Nawata H. The antiobesity of dehydroepiandrosterone in castrated or noncastrated obese Zucker male rats. Obes Res. 1995;1(Suppl 5):639–43.
Villareal DT, Holloszy JO, et al. Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial. JAMA. 2004;292:2243–8.
McNelis JC, Manolopoulos KN, Gathercole LL, Bujalska IJ, Stewart PM, Tomlinson JW, et al. Dehydroepiandrosterone exerts antiglucocorticoid action on human preadipocyte proliferation, differentiation, and glucose uptake. Am J Physiol Endocrinol Metab. 2013;305(9):E1134–44.
Ashida K, Goto K, Zhao Y, Okabe T, Yanase T, Takayanagi R, et al. Dehydroepiandrosterone negatively regulates the p38 mitogen-activated protein kinase pathway by a novel mitogen-activated protein kinase phosphatase. Biochim Biophys Acta. 2005;1728(1–2):84–94.
Watanabe T, Ashida K, Goto K, Nawata H, Takayanagi R, Yanase T, et al. Dehydroepiandrosterone-enhanced dual specificity protein phosphatase (DDSP) prevents diet -induced and genetic obesity. Biochem Biophys Res Commun. 2015;468(1–2):196–201.